EVIDENCE THAT TRANSMITTER-CONTAINING DYSTROPHIC NEURITES PRECEDE PAIRED HELICAL FILAMENT AND ALZ-50 FORMATION WITHIN SENILE PLAQUES IN THE AMYGDALA OF NONDEMENTED ELDERLY AND PATIENTS WITH ALZHEIMERS-DISEASE

Immunocytochemical techniques were employed to examine the temporal ordering whereby amyloid beta-protein (AbetaP) and neuronal elements collectively come together to form senile plaques in Alzheimer's disease (AD). Specifically, we addressed three questions: (1) whether AbetaP deposition precedes or follows neuritic changes; (2) whether paired helical filament (PHF) formation is an early or late event in the genesis of the dystrophic neurites which participate in plaque formation; and (3) whether the density of senile plaques displays any relationship with the prevalence of PHF or Alz-50 containing neurons. To address these questions we studied the amygdala from a group of patients with AD, a group of nondemented age-matched individuals exhibiting a sufficient number of senile plaques to be classified by neuropathological criteria as AD, and a group of age-matched controls without AD pathology. Amyloid-bearing plaques were demonstrated by AbetaP immunolabeling and thioflavine-S staining. Neuritic changes in the form of dystrophic neurites were observed with the aid of antibodies against PHF, Alz-50, as well as antibodies against several neuropeptides (i.e., substance P, somatostatin, and neurotensin) and the acetylcholine biosynthetic enzyme, choline acetyltransferase. By using a graded range of pathologic changes both within and across the patient population to provide us with a means of evaluating plaque deposition from its earliest to most advanced stages of development, we observed in patients and/or regions of the amygdala displaying a mild degree of pathologic change AbetaP deposition in the absence of any neuritic changes. With increasing density of AbetaP, however, we began to observe dystrophic neurites within plaques. In regions of relatively few plaques, the dystrophic neurites were immunolabeled only with antibodies against the various neurotransmitters and they lacked evidence of cytoskeletal pathology (i.e., Alz-50 or PHF). Only as the density of AbetaP increased further within a region, were dystrophic neurites observed that exhibited Alz-50 or PHF. In no instance did we observe a relationship between the density of AbetaP deposition and the density of Alz-50 or PHF-immunoreactive neurons. Collectively, our data suggest that the deposition of AbetaP is an early pathologic event in senile plaque formation. Thereafter, swollen neurites can be seen in the vicinity of AbetaP. This early neuritic response, which can first be visualized by immunolabeling for one or another transmitter substance, is followed by alterations in the cytoskeleton as recognized initially by antibodies to Alz-50 and subsequently by the presence of PHF. (C) 1993 Wiley-Liss, Inc.